Ken Grime

1.5k total citations
36 papers, 1.1k citations indexed

About

Ken Grime is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Ken Grime has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 16 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Ken Grime's work include Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (11 papers) and Inhalation and Respiratory Drug Delivery (6 papers). Ken Grime is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (11 papers) and Inhalation and Respiratory Drug Delivery (6 papers). Ken Grime collaborates with scholars based in United Kingdom, Sweden and United States. Ken Grime's co-authors include Robert J. Riley, Dermot F. McGinnity, Matthew G. Soars, Jane R. Kenny, Douglas Ferguson, Peter J. H. Webborn, Anne Cooper, Richard Weaver, Anthony C. Atkinson and Stuart W. Paine and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Trends in Pharmacological Sciences.

In The Last Decade

Ken Grime

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Grime United Kingdom 18 557 404 271 188 152 36 1.1k
Rhys D.O. Jones United Kingdom 14 400 0.7× 306 0.8× 264 1.0× 243 1.3× 95 0.6× 32 925
Martin K. Bayliss United Kingdom 18 613 1.1× 414 1.0× 344 1.3× 203 1.1× 71 0.5× 32 1.4k
Philip Wastall United States 6 525 0.9× 349 0.9× 350 1.3× 196 1.0× 61 0.4× 8 1.2k
Stuart W. Paine United Kingdom 18 306 0.5× 237 0.6× 270 1.0× 263 1.4× 71 0.5× 61 993
Rowan Stringer Switzerland 17 267 0.5× 216 0.5× 232 0.9× 99 0.5× 180 1.2× 23 874
Matthew G. Soars United States 20 979 1.8× 785 1.9× 378 1.4× 128 0.7× 66 0.4× 32 1.6k
Jane R. Kenny United States 24 996 1.8× 707 1.8× 442 1.6× 237 1.3× 56 0.4× 58 1.8k
Ping Kang United States 20 447 0.8× 208 0.5× 367 1.4× 142 0.8× 122 0.8× 29 1.1k
Stephen Fowler Switzerland 22 560 1.0× 314 0.8× 321 1.2× 149 0.8× 39 0.3× 47 1.1k
David R. Jones United States 19 979 1.8× 765 1.9× 576 2.1× 135 0.7× 111 0.7× 35 2.3k

Countries citing papers authored by Ken Grime

Since Specialization
Citations

This map shows the geographic impact of Ken Grime's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Grime with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Grime more than expected).

Fields of papers citing papers by Ken Grime

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Grime. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Grime. The network helps show where Ken Grime may publish in the future.

Co-authorship network of co-authors of Ken Grime

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Grime. A scholar is included among the top collaborators of Ken Grime based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Grime. Ken Grime is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monkley, Susan J., D Smith, Richard Hewitt, et al.. (2023). Epithelial senescence in idiopathic pulmonary fibrosis is propagated by small extracellular vesicles. Respiratory Research. 24(1). 51–51. 17 indexed citations
2.
Davies, Michael, Rhys D.O. Jones, Ken Grime, et al.. (2020). Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades. Trends in Pharmacological Sciences. 41(6). 390–408. 85 indexed citations
3.
Hamm, Grégory, Anna Nilsson, Nicole Strittmatter, et al.. (2019). Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(1). 43–53. 16 indexed citations
4.
Gardiner, Philip, Rhona J. Cox, & Ken Grime. (2019). Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metabolism and Disposition. 47(8). 865–873. 20 indexed citations
5.
Fridén, Markus, et al.. (2017). Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data. Pharmaceutical Research. 34(12). 2557–2567. 12 indexed citations
6.
Bergström, Fredrik, et al.. (2017). Intrinsic Clearance Assay Incubational Binding: A Method Comparison. Drug Metabolism and Disposition. 45(4). 342–345. 16 indexed citations
7.
Austin, Rupert P., Roger V. Bonnert, Anthony R. Cook, et al.. (2015). Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 25(7). 1616–1620. 16 indexed citations
8.
Mete, Antonio, Keith Bowers, Richard J. Bull, et al.. (2013). The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD. Bioorganic & Medicinal Chemistry Letters. 23(23). 6248–6253. 8 indexed citations
9.
10.
Grime, Ken & Stuart W. Paine. (2012). Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement. Drug Metabolism and Disposition. 41(2). 372–378. 36 indexed citations
11.
12.
Morley, Andrew, Bryan Roberts, Barry Teobald, et al.. (2011). Lead optimisation of pyrazoles as novel FPR1 antagonists. Bioorganic & Medicinal Chemistry Letters. 22(1). 532–536. 14 indexed citations
13.
Mete, Antonio, Keith Bowers, Éric Chevalier, et al.. (2011). The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorganic & Medicinal Chemistry Letters. 21(24). 7440–7446. 13 indexed citations
14.
Grime, Ken, Peter J. H. Webborn, & Robert J. Riley. (2008). Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes. Drug Metabolism and Disposition. 36(8). 1670–1678. 23 indexed citations
15.
Soars, Matthew G., et al.. (2007). Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo. Drug Metabolism and Disposition. 35(6). 859–865. 117 indexed citations
16.
O’Donnell, Colm P., et al.. (2006). The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting. Drug Metabolism and Disposition. 35(3). 381–385. 27 indexed citations
17.
McGinnity, Dermot F., et al.. (2006). EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES. Drug Metabolism and Disposition. 34(8). 1291–1300. 69 indexed citations
18.
Cumming, John G., S Brown, Anne Cooper, et al.. (2006). Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides. Bioorganic & Medicinal Chemistry Letters. 16(13). 3533–3536. 15 indexed citations
19.
Atkinson, Anthony C., Jane R. Kenny, & Ken Grime. (2005). AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS. Drug Metabolism and Disposition. 33(11). 1637–1647. 79 indexed citations
20.
Cumming, John G., Anne Cooper, Ken Grime, et al.. (2005). Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides. Bioorganic & Medicinal Chemistry Letters. 15(22). 5012–5015. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rhys D.O. Jones Breakdown of academic impact, for papers by Martin K. Bayliss Breakdown of academic impact, for papers by Philip Wastall Breakdown of academic impact, for papers by Stuart W. Paine Breakdown of academic impact, for papers by Rowan Stringer Breakdown of academic impact, for papers by Matthew G. Soars Breakdown of academic impact, for papers by Jane R. Kenny Breakdown of academic impact, for papers by Ping Kang Breakdown of academic impact, for papers by Stephen Fowler Breakdown of academic impact, for papers by David R. Jones
Rankless by CCL
2026